A biotech founded by a 32-year-old just failed a key Alzheimer's drug trial (AXON)
Axovant, a company founded by 32-year-old Vivek Ramaswamy, just failed a key late-stage trial for its Alzheimer's drug.
Axovant is the latest in a series of failures to get an Alzheimer's drug approved. 99% of all Alzheimer's drugs have failed clinical trials in the past decade.
There are only four approved drugs that treat the symptoms of the disease, which affects more than 5 million Americans.
The most recent drug approval happened in 2003.
"While we are deeply disappointed by these trial results, we also are saddened for the millions of patients and families impacted by Alzheimer's disease," Axovant CEO David Hung said. "However, we believe that the fight against Alzheimer's and other important areas of unmet need in neurology is too important to be derailed by this setback."
The hope for the drug, called intepirdine, was to combine it with donepezil, an Alzheimer's drug currently in use. Taken together, the two seemed to slow the loss of cognition and ability to perform daily tasks more effectively than when donepezil was taken alone.
Why it might not have been the 'breakthrough' people are looking for
The goal of the drug was to treat the symptoms associated with the disease, such as cognition and behavior changes. intepirdine, as far as researchers know, can't reverse the effects of Alzheimer's or cure the disease. More realistically, Axovant CEO David Hung said in August he was hopeful they might find a disease-modifying effect, which could push back the timeline on the disease.
Axovant wasn't the only drug that's taken this approach: In February, Danish drugmaker Lundbeck said two of its trials on the company's 5HT6 antagonist had failed. In 2016, Pfizer shut down its trials on a drug that acted on the 5HT6 receptor as well.
Even though intepirdine failed, Hung still has big plans for Axovant.
The company's also looking at how intepirdine works in people who have Lewy Body Dementia, a neurodegenerative disease with symptoms that look like Alzheimer's or Parkinson's. In that trial, people received a higher dose of intepirdine. It's expected to have results by the end of the year. Axovant also has three other drugs, which are earlier in development.
NOW WATCH: Here's what makes tech stocks today different from the tech bubble
No comments: